Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Supply readiness follows months of manufacturing to ensure timely and ample supply
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
This product will be manufactured at Lupin's Pithampur facility in India
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
